福瑞达: 鲁商福瑞达医药股份有限公司关于取消监事会及修订《公司章程》和部分治理制度的公告

Group 1 - The company has decided to abolish the supervisory board and amend its articles of association and governance systems to comply with the new Company Law effective from July 1, 2024 [1][2] - The supervisory board's functions will be transferred to the audit committee of the board of directors, and relevant rules regarding the supervisory board will be abolished [1][2] - The amendments to the articles of association are based on the latest regulations from the Company Law, the Guidelines for Articles of Association of Listed Companies, and the Shanghai Stock Exchange Listing Rules [2][3] Group 2 - The company was established as a joint-stock company in 1993, with major sponsors including Wan Jie Group and several textile and chemical factories [3][4] - The company underwent a restructuring in 1998, merging with Shandong Zibo Wanjie Medical Co., Ltd., and received a new certificate of approval from the provincial government [4] - The company has undergone several regulatory confirmations and has been compliant with the Company Law since its establishment [4][5] Group 3 - The company aims to enhance its operational standards and governance in line with legal requirements and its actual circumstances [1][2] - The governance structure will be revised to ensure compliance with the latest legal frameworks and to improve the company's operational efficiency [1][2] - The company is committed to maintaining the rights and interests of its shareholders while ensuring a transparent and fair governance process [1][2]